Loading...
ROCO
4743
Market cap982mUSD
May 14, Last price  
62.30TWD
1D
1.47%
1Q
-20.43%
Jan 2017
81.63%
IPO
49.90%
Name

Oneness Biotech Co Ltd

Chart & Performance

D1W1MN
ROCO:4743 chart
P/E
—
P/S
252.67
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.82%
Rev. gr., 5y
54.32%
Revenues
118m
+35.89%
1,631,00059,093,0003,715,0008,597,0004,609,0005,479,0007,841,0005,703,0002,587,00018,856,00013,475,00041,605,00065,765,0001,065,554,00086,783,000117,926,000
Net income
-1.17b
L-11.25%
6,280,000953,00013,956,000-27,390,000276,253,000199,726,000-93,017,000-14,257,000-155,446,000-235,436,000-328,463,000-251,679,000-412,823,000359,975,000-1,312,867,000-1,165,147,000
CFO
-346m
L-18.14%
-102,299,000153,245,000-29,266,00024,153,000-89,262,000-150,980,000-142,345,000-108,540,000-165,268,000-5,123,000-213,252,000158,138,000-288,894,000-881,001,000-422,176,000-345,579,000
Dividend
Jun 16, 20230.1124 TWD/sh
Earnings
Aug 11, 2025

Profile

Oneness Biotech Co., Ltd engages in the research and development of new drugs, and sale of pharmaceutical and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis and systemic sclerosis; FB825, which is in Phase II clinical trial for treating atopic dermatitis, allergic diseases, and asthma; and FB918, a human monoclonal antibody, which is in pre-clinical stage for the treatment of allergic asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and sale of agricultural products. The company was incorporated in 2008 and is headquartered in Taipei City, Taiwan.
URL
https://www.onenessbio.com/tc/index.htm
IPO date
Jun 19, 2009
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
117,926
35.89%
86,783
-91.86%
1,065,554
1,520.24%
Cost of revenue
1,203,341
1,183,408
1,307,001
Unusual Expense (Income)
NOPBT
(1,085,415)
(1,096,625)
(241,447)
NOPBT Margin
Operating Taxes
3,289
5,290
99,732
Tax Rate
NOPAT
(1,088,704)
(1,101,915)
(341,179)
Net income
(1,165,147)
-11.25%
(1,312,867)
-464.71%
359,975
-187.20%
Dividends
(39,091)
Dividend yield
0.04%
Proceeds from repurchase of equity
54,910
254,112
344,117
BB yield
-0.13%
-0.28%
-0.36%
Debt
Debt current
41,179
90,143
13,356
Long-term debt
771,529
830,147
513,428
Deferred revenue
170,684
145,991
Other long-term liabilities
470
253,118
480
Net debt
(3,971,987)
(10,948,816)
(9,048,253)
Cash flow
Cash from operating activities
(345,579)
(422,176)
(881,001)
CAPEX
(52,105)
(90,057)
(89,185)
Cash from investing activities
544,164
(4,819,650)
5,735,919
Cash from financing activities
19,703
386,581
451,869
FCF
(1,067,699)
(1,328,345)
(234,276)
Balance
Cash
7,018,948
7,772,961
8,046,739
Long term investments
(2,234,253)
4,096,145
1,528,298
Excess cash
4,778,799
11,864,767
9,521,759
Stockholders' equity
4,137,449
5,472,859
6,317,152
Invested Capital
9,239,953
9,709,730
8,960,082
ROIC
ROCE
EV
Common stock shares outstanding
477,519
473,402
447,943
Price
87.30
-54.88%
193.50
-9.95%
214.88
-25.26%
Market cap
41,687,432
-54.49%
91,603,328
-4.83%
96,253,907
-22.81%
EV
38,216,461
81,098,581
87,467,937
EBITDA
(631,001)
(648,119)
253,189
EV/EBITDA
345.46
Interest
9,609
5,610
4,595
Interest/NOPBT